A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2019 Status changed from suspended to active, no longer recruiting.
- 13 Dec 2018 Planned End Date changed from 30 Nov 2018 to 31 Dec 2021.
- 13 Dec 2018 Planned primary completion date changed from 30 Nov 2018 to 31 Dec 2021.